Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$3.1B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. operates in the health care sector, specifically in biotechnology....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GRAIL is managing its costs and revenue.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its cancer detection products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. operates in the health care sector, specifically in biotechnology. The company focuses on early cancer detection through advanced blood tests, which is increasingly important as early diagnosis can significantly improve treatment outcomes.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1 2026, GRAIL reported an EPS loss of $-2.29, which was better than the expected loss of $-3.00, marking a positive surprise. However, the stock fell 2.26% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for GRAIL's upcoming earnings are cautious, given the company's history of losses but consistent surprises in EPS. Investors will be closely watching for any signs of revenue growth or improvements in operational efficiency.

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal improving financial health and investor confidence, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows no signs of revenue growth, it could lead to further declines in stock price, reflecting ongoing concerns about its long-term viability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given GRAIL's history of beating EPS estimates, this number will be critical in assessing the company's financial health and market confidence.

What are the revenue figures for the quarter?

Revenue growth is essential for GRAIL's sustainability, and any signs of improvement will be closely scrutinized by investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GRAIL's ability to manage costs effectively, leading to a better-than-expected EPS outcome this quarter.

Supporting Evidence

GRAIL has consistently beaten EPS estimates in the past, indicating potential for another surprise.

The options market is pricing in a significant move, suggesting traders expect volatility that could favor a positive outcome.

Key Risk

If GRAIL's EPS comes in better than -$2.00, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether GRAIL can continue its trend of EPS surprises while also showing signs of revenue growth.

Bull Confirmed If

An EPS of less than -$2.00 would confirm the bull case, indicating better-than-expected cost management.

Bear Confirmed If

An EPS worse than -$3.00 would confirm the bear case, suggesting ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move in either direction, suggesting that traders expect volatility around the earnings report.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests a potential stock increase of around 1.90%, confirming positive momentum.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could experience mixed reactions based on management commentary.

Miss

If GRAIL misses expectations, the stock could decline, with historical patterns suggesting an average drop of around 2.26%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trials.
2Management's commentary on cost management strategies.
3Insights into market demand for GRAIL's cancer detection tests.
4Any partnerships or collaborations that could enhance revenue.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. operates in the health care sector, specifically in biotechnology....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GRAIL is managing its costs and revenue.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its cancer detection products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal improving financial health and investor confidence, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows no signs of revenue growth, it could lead to further declines in stock price, reflecting ongoing concerns about its long-term viability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given GRAIL's history of beating EPS estimates, this number will be critical in assessing the company's financial health and market confidence.

What are the revenue figures for the quarter?

Revenue growth is essential for GRAIL's sustainability, and any signs of improvement will be closely scrutinized by investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GRAIL's ability to manage costs effectively, leading to a better-than-expected EPS outcome this quarter.

Supporting Evidence

GRAIL has consistently beaten EPS estimates in the past, indicating potential for another surprise.

The options market is pricing in a significant move, suggesting traders expect volatility that could favor a positive outcome.

Key Risk

If GRAIL's EPS comes in better than -$2.00, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether GRAIL can continue its trend of EPS surprises while also showing signs of revenue growth.

Bull Confirmed If

An EPS of less than -$2.00 would confirm the bull case, indicating better-than-expected cost management.

Bear Confirmed If

An EPS worse than -$3.00 would confirm the bear case, suggesting ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move in either direction, suggesting that traders expect volatility around the earnings report.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests a potential stock increase of around 1.90%, confirming positive momentum.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could experience mixed reactions based on management commentary.

Miss

If GRAIL misses expectations, the stock could decline, with historical patterns suggesting an average drop of around 2.26%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trials.
2Management's commentary on cost management strategies.
3Insights into market demand for GRAIL's cancer detection tests.
4Any partnerships or collaborations that could enhance revenue.
5Guidance on future revenue expectations.